Understanding vaccine responses in immunocompromised patients
Prospective Cohort-study for the Investigation of the Vac-cine-induced Immune Response After Vaccination Against RESPiratory Viral Infections in Immunocompromised Pa-tients With or Without Haemato-ONcological diseaSEs
This study looks at how well vaccines work for people with weakened immune systems, like those with blood cancers or on certain treatments, to help improve their protection against respiratory viruses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Cologne Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Cologne, North Rhine-Westphalia) |
| Trial ID | NCT06612515 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the immune responses to vaccinations against respiratory viruses in immunocompromised patients. It focuses on both early and late booster vaccinations, particularly examining virus-specific T cell responses. The study addresses the challenges faced by patients with conditions such as hematological malignancies and those undergoing immunosuppressive therapies, who are at higher risk for severe infections. By gathering immunologic data, the study seeks to improve vaccination strategies for this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are immunocompromised due to treatment or underlying diseases and are willing to be vaccinated against respiratory viruses.
Not a fit: Patients who are unwilling or ineligible for vaccination under current recommendations may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance vaccination effectiveness and reduce the risk of severe respiratory infections in immunocompromised patients.
How similar studies have performed: While there is limited data specifically on T cell responses in this context, similar studies have shown promise in improving vaccination strategies for immunocompromised populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent form * Patients with immunosuppression either by treatment or underlying diseases * Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in ac-cordance with current recommendations * Age of 18 years or older Exclusion Criteria: * Patients unwilling/ineligible for vaccination under current recommendations
Where this trial is running
Cologne, North Rhine-Westphalia
- University Hospital Cologne — Cologne, North Rhine-Westphalia, Germany (Recruiting)
Study contacts
- Study coordinator: Sibylle Mellinghoff, MD
- Email: sibylle.mellinghoff@uk-koeln.de
- Phone: +4947885523
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.